<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01000467</url>
  </required_header>
  <id_info>
    <org_study_id>009-KOB-0801i</org_study_id>
    <nct_id>NCT01000467</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Study for Probucol</brief_title>
  <official_title>A Randomized, Open-label, Single-center Clinical Trial to Evaluate the Safety and Pharmacokinetics of Probucol by Multiple Administration in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and pharmacokinetics of probucol by multiple oral administration in
      healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and pharmacokinetics of probucol by multiple oral administration of
      one 250-mg probucol tablet once daily after breakfast (250 mg/day), two 250-mg probucol
      tablets once daily after breakfast (500 mg/day), and one 250-mg probucol tablet twice daily
      after breakfast and dinner (500 mg/day) for 14 days in healthy male subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma pharmacokinetic (PK) parameters: Auc, Cmax etc.</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2(probucol 500mg BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1(Probucol 250mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 3(Probucol 500mg once daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>probucol</intervention_name>
    <description>group 3: 250 mg 1 tablet in the morning and evening</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Brand name: Lorelco</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>probucol</intervention_name>
    <description>group 1: 250 mg</description>
    <arm_group_label>1</arm_group_label>
    <other_name>lorelco</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>probucol</intervention_name>
    <description>group 2: 250 mg 2 tablets at once in the morning</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Lorelco</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Korean

          -  Male

          -  Age from 20 to 40 years at time of informed consent

          -  BMI more than 19.0 and less than 25.0

          -  Subjects who meet the following criteria at the time of the screening

          -  Subjects with ECG results without AV block and with both of qTc and QRS width within
             the standard values

        Exclusion criteria

          -  History or clinical evidence of significant medical history

          -  Present or previous significant drug allergy to any prescription or OTC medication
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yoo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Trial Center, Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul national univeristy</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2009</study_first_submitted>
  <study_first_submitted_qc>October 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2009</study_first_posted>
  <last_update_submitted>October 21, 2009</last_update_submitted>
  <last_update_submitted_qc>October 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Yonghui Jeong/Clinical Research Manager</name_title>
    <organization>Korea Otsuka Pharma</organization>
  </responsible_party>
  <keyword>PK assessment for healthy male volunteer</keyword>
  <keyword>Healthy male subjects aged 20 to 40 years</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Probucol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

